Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 9, 2006, Pages 811-818

  Nagpal, Madan L ^a,b   Davis, Jeffrey ^b   Lin, Tu ^a,b  

^a WJB Dorn VA Medical Center   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation; CXCL10; CXCR3; Prostate cancer; PSA

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; COMPLEMENTARY DNA; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINES, CXC; GENE EXPRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR3; TRANSFECTION;

HUMAN PAPILLOMAVIRUS;

EID: 33748755958     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.06.017     Document Type: Article

References (42)

1. Schroder F.H. Endocrine treatment of prostate cancer. In: Walsh P.C., Retik A.B., Vaughan E.D., and Wein A.J. (Eds). Campbell's Urology (1998), WB Saunders, Philadelphia 2627-2644
2. Unni E., Sun S., Nan B., McPhaul M.J., Cheskis B., Mancini M.A., and Marcelli M. Changes in androgen receptor non-genomic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64 (2004) 7156-7168
3. Zhou J.R., Yu L., Zerbini L.F., Libermann T.A., and Blackburn G.L. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int. J. Cancer 110 (2004) 800-806
4. Platz E.A., and De Marzo A.M. Epidemiology of inflammation and prostate cancer. J. Urol. 171 2Pt2 (2004) S36-S40
5. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., Taub D.T., Iannettoni M.D., Whyte R.I., and Streiter R.M. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184 (1996) 981-992
6. Giese N.A., Raykov Z., DeMartino L., Cecchi A., Suzzani S., Dinsart C., Cornelis J.J., and Rommelaere J. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 9 (2002) 432-442
7. Soejima K., and Rollins B.J. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan. J. Immunol. 16 (2001) 6576-6582
8. Hu J., You S., Li W., Wang D., Nagpal M.L., Mi Y., Liang P., and Lin T. Expression and regulation of interferon-γ-inducible protein-10 (IP-10) gene in rat Leydig cells. Endocrinology 139 (1998) 3637-3645
9. Goffic R.L., Mouchel T., Aubry F., Patard J.J., Ruffault A., Jegou B., and Samson M. Production of the chemokines monocyte chemotactic protein-1, regulated on activation normal T cell expressed and secreted protein, growth-related oncogene, and interferon-γ-inducible protein-10 is induced by the Sandai virus in human and rat testicular cells. Endocrinology 143 (2002) 1434-1440
10. Shen H., and Lentsch A.B. Progressive dysregulation of transcription factors NF-κB and STAT1 prostate cancer cells causes proangiogenic production of CXC chemokines. Am. J. Physiol. Cell Physiol. 286 (2004) C840-C847
11. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65 (2005) 1635-1641
12. Sinha-Hikim I., Taylor W.E., Gonzalez-Cadavid N.F., Zhang W., and Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J. Clin. Endocrinol. Metab. 89 (2004) 5245-5255
13. Diez C., Nestler M., Friedrich U., Vieh M., Stolte M., Hu K., Hoppe J., and Simm A. Down-regulation of Akt/PKB in senescent cardiac fibroblasts impairs PDGF-induced cell proliferation. Cardiovasc. Res. 49 (2001) 731-740
14. Joyce N.C., Harris D.L., Alister J.C.M., Ali R.R., and Larkin D.F.P. Effect of overexpressing the transcription factor E2F2 on cell cycle progression in rabbit corneal endothelial cells. Investig. Ophthalmol. Vis. Sci. 45 (2004) 1340-1348
15. Nagpal M.L., Chen Y., and Lin T. Effects of overexpression of CXCL10 (cytokine-responsive gene-2) on MA-10 mouse Leydig tumor cell steroidogenesis and proliferation. J. Endocrinol. 183 (2004) 585-594
16. Rossi D., and Zlotnik A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18 (2000) 217-242
17. Wang X., Yue T.L., Ohlstein E.H., Sung C.P., and Feuerstein G.Z. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J. Biol. Chem. 27 (1996) 24286-24293
18. Luster A.D., Greenberg S.M., and Leder P. The IP-10 chemokine binds to a specific cell surface heparin sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182 (1995) 219-231
19. Murphy P.M., Baggiolini M., Charo I.F., Herbert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., and Power C.A. International union of pharmacology. XXII. Nomenclature for chemokines receptors. Pharmacol. Rev. 52 (2000) 145-176
20. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
21. Lasagni L.A., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., and Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC and acts as functional receptor for platelet factor 4. J. Exp. Med. 197 (2003) 1537-1549
22. Ehlert J.E., Addison C.A., Burdick M.D., Kunkel S.L., and Strieter R.M. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J. Immunol. 173 (2004) 6234-6240
23. Luster A.D., and Leder P. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178 (1993) 1057-1065
24. Sun H., Kundu N., Dorsey R., Jackson M.J., and Fulton A.M. Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. J. Immunother. 24 (2001) 138-143
25. Dorsey R., Kundu N., Yang Q., Tannenbaum C.S., Sun H., Hamilton T.A., and Fulton A.M. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res. 62 (2002) 2606-2610
26. Strieter R.M., Kunkel S.L., Arenberg D.A., Burdick M.D., and Polverini P.J. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210 (1995) 51-57
27. Belperio J.A., Keane M.P., Arenberg D.A., Addison C.L., Ehlert J.E., Burdick M.D., and Strieter R.M. CXC chemokines in angiogenesis. J. Leukoc. Biol. 68 (2000) 1-8
28. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I.P., and Ben-Baruch A. The expression of the chemokines receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett. 92 (2004) 171-178
29. Zeilhofer H.U., and Schorr W. Role of interleukin-8 in neutrophils signaling. Curr. Opin. Hematol. 7 (2000) 178-182
30. Sauty A., Colvin R.A., Wagner L., Rochat S., Spertini F., and Luster A.D. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell á chemoattractant (CXCL11). J. Immunol. 167 (2001) 7084-7093
31. Xing N., Chen Y., Mitchell S.H., and Young C.Y.F. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22 (2001) 409-414
32. Moilanen A.M., Karvonen U., Poukka H., Janne O.A., and Palvimo J.J. Activation of androgen receptor function by a novel nuclear protein. Mol. Biol. Cell 9 (1998) 2527-2543
33. Nishida T., and Yasuda H. PIASI and PIASX alpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J. Biol. Chem. 277 (2002) 41311-41317
34. Fu M., Rao M., and Wu K. The androgen receptor acetylation site regulates cAMP and AKT, but not ERK-induced activity. J. Biol. Chem. 279 (2004) 29436-29449
35. Hayes S.A., Zarnegar M., Sharma M., Yang F., Peehl D.M., Dijke P.T., and Sun Z. SMAD3 represses androgen receptor mediated transcription. Cancer Res. 61 (2001) 2112-2118
36. Culig Z., Comuzzi B., Steiner H., Bartsch G., and Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 92 (2004) 265-271
37. Romagnani P., Annunziato F., Lasagni L., Lazzeri E., Beltrame C., Francalanci M., Uguccioni M., Galli G., Cosmi L., Maurenzig L., Baggiolini M., Maggi E., Romagnani S., and Srio M. Cell cycle-dependent expression of CXC chemokines receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107 (2001) 53-63
38. Romagnani P., Beltrame C., Annunziato F., Lasgni L., Luconi M., Galli G., Cosmi L., Maggi E., Salvadori M., Pupilli C., and Serio M. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J. Am. Soc. Nephrol. 10 (1999) 2518-2526
39. Feldman A.L., Friedl J., Lans T.E., Libutti .S.K., Lorang D., Miller M.S., Turner E.M., Hewitt S.M., and Alexander H.R. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int. J. Cancer 99 (2002) 149-153
40. Tannenbaum C.S., Tubbs R., Armstrong D., Finke J.H., Bukowski R.M., and Hamilton T.A. The CXC chemokines IP-10 and Mig are necessary for IL-12 mediated regression of mouse RENCA tumor. J. Immunol. 161 (1998) 927-932
41. Kanegane C., Sgadari C., Kanegane H., Terrya-Feldstei J., Yao L., Gupta G., Farber J.M., Liu L., and Tosato G. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukoc. Biol. 64 (1998) 384-392
42. Palmer K., Hitt M., Emtage P.C.R., Gyorffy S., and Gauldie J. Combined CXC chemokines and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 8 (2001) 282-290